Gleason Carey E, Fischer Barbara L, Dowling N Maritza, Setchell Kenneth D R, Atwood Craig S, Carlsson Cynthia M, Asthana Sanjay
Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
J Alzheimers Dis. 2015;47(4):1009-19. doi: 10.3233/JAD-142958.
In a previous trial, treatment with soy isoflavones was associated with improved nonverbal memory, construction abilities, verbal fluency, and speeded dexterity compared to treatment with placebo in cognitively healthy older adults.
The current trial aimed to examine the potential cognitive benefits of soy isoflavones in patients with Alzheimer's disease.
Sixty-five men and women over the age of 60 were treated with 100 mg/day soy isoflavones, or matching placebo capsules for six months. APOE genotype was determined for all participants. Cognitive outcomes and plasma isoflavone levels were measured at baseline, and at two additional time points: three and six months after baseline.
Of the sixty-five participants enrolled, thirty-four (52.3% ) were women, and 31 (47.7% ) were APOEɛ4 positive. Average age was 76.3 (SD = 7.2) years. Fifty-nine (90.8% ) subjects completed all study visits. Plasma isoflavone levels increased in subjects treated with soy isoflavones compared to baseline and to placebo, although intersubject variability in plasma levels was large. No significant differences in treatment effects for cognition emerged between treatment groups or genders. Exploratory analyses of associations between changes in cognition and plasma isoflavone levels revealed an association between equol levels, and speeded dexterity and verbal fluency.
Six months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease. However, our results suggest the need to examine the role of isoflavone metabolism, i.e., the ability to effectively metabolize soy isoflavones by converting daidzen to equol when attempting to fully clarify the cognitive effects of isoflavones.
在之前的一项试验中，与认知健康的老年人服用安慰剂相比，服用大豆异黄酮与非语言记忆、构建能力、语言流畅性及敏捷度提高有关。
当前试验旨在研究大豆异黄酮对阿尔茨海默病患者潜在的认知益处。
65名60岁以上的男性和女性服用100毫克/天的大豆异黄酮或匹配的安慰剂胶囊，为期6个月。测定所有参与者的载脂蛋白E（APOE）基因型。在基线以及另外两个时间点（基线后3个月和6个月）测量认知结果和血浆异黄酮水平。
在登记的65名参与者中，34名（52.3%）为女性，31名（47.7%）APOEɛ4呈阳性。平均年龄为76.3（标准差=7.2）岁。59名（90.8%）受试者完成了所有研究访视。与基线和安慰剂相比，服用大豆异黄酮的受试者血浆异黄酮水平升高，尽管血浆水平的个体间变异性较大。治疗组或性别之间在认知治疗效果上没有显著差异。对认知变化与血浆异黄酮水平之间关联的探索性分析显示，雌马酚水平与敏捷度及语言流畅性之间存在关联。
对于患有阿尔茨海默病的老年男性和女性，每天服用100毫克大豆异黄酮6个月对认知没有益处。然而，我们的结果表明，在试图充分阐明异黄酮的认知作用时，有必要研究异黄酮代谢的作用，即通过将大豆苷元转化为雌马酚来有效代谢大豆异黄酮的能力。
